Cargando…
Use of RWE to Inform Regulatory, Public Health Policy, and Intervention Priorities for the Developing World
For low‐ and middle‐income countries (LMICs) to benefit from real‐world evidence (RWE)/real‐world data (RWD) in both product registration (“regulatory”) decision making and in product utilization policy (“policy”) decision making, they need to overcome several challenges. They need to deploy more el...
Autores principales: | McNair, Douglas, Lumpkin, Murray, Kern, Steven, Hartman, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9298255/ https://www.ncbi.nlm.nih.gov/pubmed/34655224 http://dx.doi.org/10.1002/cpt.2449 |
Ejemplares similares
-
Real world evidence (RWE) - Are we (RWE) ready?
por: Suvarna, Viraj Ramesh
Publicado: (2018) -
Real-world evidence (RWE): A challenge for regulatory agencies discussion of the RWE conference with the network of the european medicine agencies, patients, and experts
por: Maison, Patrick, et al.
Publicado: (2022) -
Harnessing the Power of Real‐World Evidence (RWE): A Checklist to Ensure Regulatory‐Grade Data Quality
por: Miksad, Rebecca A., et al.
Publicado: (2017) -
Paving the way for patient centricity in real-world evidence (RWE): Qualitative interviews to identify considerations for wider implementation of patient-reported outcomes in RWE generation
por: Maruszczyk, Konrad, et al.
Publicado: (2023) -
Developing a multi-center clinical data mart of ACEI and ARB for real-world evidence (RWE)
por: Kim, Hun-Sung, et al.
Publicado: (2018)